Homozygous Familial Hypercholesterolemia (HoFH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Homozygous familial hypercholesterolemia (HoFH) is a genetic condition characterized by profound elevations in low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels. HoFH significantly raises the risk of premature coronary artery disease. This condition is associated with a deficiency or absence of LDL-C receptors, which can be attributed to mutations affecting the binding site of apolipoprotein B-100 (apoB-100) on LDL-C receptors and mutations in PCSK9 and LDLRAP1. The LDLR gene is situated on chromosome 19’s short arm. LDL-C receptors play a vital role in the liver’s uptake of approximately 70% of circulating LDL-C molecules. A decrease in LDL-C receptors results in accelerated cholesterol deposition within arterial walls. This, in turn, leads to arterial hardening, narrowing, and reduced blood flow, predisposing individuals to cardiovascular diseases such as stroke and myocardial infarction.
• In the United States, as of 2020, the estimated prevalence of HoFH ranged from 1 to 2.5 cases per 160,000 to 300,000 individuals, marking a notable increase from prior estimates.

Thelansis’s “Homozygous Familial Hypercholesterolemia (HoFH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Homozygous Familial Hypercholesterolemia (HoFH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Homozygous Familial Hypercholesterolemia (HoFH) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Homozygous Familial Hypercholesterolemia (HoFH) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Homozygous Familial Hypercholesterolemia (HoFH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Homozygous Familial Hypercholesterolemia (HoFH), Homozygous Familial Hypercholesterolemia (HoFH) market outlook, Homozygous Familial Hypercholesterolemia (HoFH) competitive landscape, Homozygous Familial Hypercholesterolemia (HoFH) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)